{"Clinical Trial ID": "NCT01790932", "Intervention": ["INTERVENTION 1:", "BKM120", "BKM120: 100 mg capsule once daily in a 28-day cycle.", "The treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons."], "Eligibility": ["Incorporation criteria:", "A metastatic and radiologically confirmed triple negative breast cancer", "Up to two previous lines of chemotherapy for metastatic breast cancer", "Availability of a representative tumour sample", "At least one measurable injury", "- Exclusion criteria:", "Have already been treated with PI3K inhibitors", "- Symptomatic central nervous system (CNS) metastases (controlled and asymptomatic CNS metastases are acceptable)", "\u2022 Concomitant malignancy or malignancy within 3 years of enrollment in the study", "One of the following mood disorders: major active depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, history of attempted or suicidal ideation, homicide ideas, greater or greater than common criteria for Grade 3 Adverse Event Anxiety (CAAE) toxicity", "At the same time, use another approved or experimental anti-neoplastic agent and/or chemotherapy within 21 days of being enrolled in this study.", "Has received radiation therapy within 28 days of being enrolled in this study or has not recovered any side effects of such therapy", "\u2022 Major surgery within 28 days of starting treatment or has not recovered any major side effects from previous surgery", "Poorly controlled diabetes", "\u2022 History of cardiac dysfunction", "During treatment with QT prolongation therapy and treatment cannot be stopped or changed to another medicine", "gastrointestinal impairment (GI) or gastrointestinal disease that may significantly affect BKM120 absorption", "\u2022 Receives chronic treatment with steroids or other immunosuppressive agents", "Other concurrent serious and/or uncontrolled medical conditions that would contraindicate participation in this study", "\u2022 History of non-compliance with a medical plan", "During treatment with medicinal products known to be moderate or potent inhibitors or inducers of the isoenzyme Cytochrome P450, family 3, subfamily A (CYP3A)", "\u2022 Known history of human immunodeficiency virus (HIV)", "Pregnant or breast-feeding", "Not wanting to observe total abstinence or use a double barrier method for birth control throughout the test"], "Results": ["Performance measures:", "Rates of clinical benefits", "By RECIST 1.1 for target lesions: CR is the complete elimination of all target lesions and PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference sum the LD. The RFP is at least a 20% increase in the total LD of target lesions (the lowest LD reference), new lesions and/or an unequivocal progression of existing non-target lesions. Stable disease (LD) is defined as any condition that does not meet the above criteria.", "Timeline: The disease was assessed radiologically at the base and every 2 cycles of treatment, then every 3 months up to 2 years. Participants in this cohort were followed to obtain an average response of approximately 2 months.", "Results 1:", "Title of arm/group: BKM120", "Description of the arm/group: BKM120: 100 mg capsule once daily in a 28-day cycle.", "The treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons.", "Total number of participants analysed: 50", "Type of measurement: Number", "Unit of measure: proportion of participants 0.12 (0.056 to 0.238)"], "Adverse Events": ["Undesirable Events 1:", "Total: 17/50 (34.0 per cent)", "Fatigue 4/50 (8.0 per cent)", "- Papulopustular eruption 1/50 (2.0%)", "Increased alanine aminotransferase 5/50 (10.00 %)", "Aspartate aminotransferase increased by 4/50 (8.0 %)", "Alcalose 1/50 (2.0%)", "Anorexia 1/50 (2.0%)", "Hyperglycaemia 2/50 (4.0%)", "Nervous system disorders - Other 1/50 (2.0%)", "1/50 dry skin (2.0%)", "1/50 acneiform Rash (2.0%)"]}